Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amantadine · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Amantadine | BEHAVIORAL | - |
Please contact site for information.
Amantadine is being investigated as a pharmacotherapy for patients with cocaine-related disorders. It is an investigational drug in clinical development for this indication, studied in a Phase 2 trial. The drug is not approved for this use and remains under evaluation.
National Healthcare Corp. (NHC) is the developer of Amantadine for cocaine-related disorders. The company is conducting clinical research on the drug for this indication, with the asset currently in Phase 2 development.
Amantadine is in Phase 2 clinical development for cocaine-related disorders. It is an investigational drug and has not been approved for this use. The Phase 2 trial has been completed, and the drug remains under clinical investigation.
Amantadine is associated with one completed Phase 2 clinical trial, NCT00000281, titled "Pharmacotherapy for Schizophrenic Drug Users - 6." The trial was conducted in the United States and included adults aged 18 years and older with cocaine-related disorders, substance-related disorders, and schizophrenia.
Amantadine is not FDA approved for cocaine-related disorders. It is an investigational drug in Phase 2 clinical development for this indication. The completed Phase 2 trial does not indicate regulatory approval, and the drug remains under study.